Key result
Digoxin-like immunoreactive substance was detected in only 23% of patients not receiving digoxin by two of four immunoassay kits, indicating less interference than previously reported.
Why the study?
Does digoxin-like immunoreactive substance (DLIS) cause significant interference in commercial digoxin immunoassays in patients with renal impairment?
Observational (n=50)
Does digoxin-like immunoreactive substance (DLIS) cause significant interference in commercial digoxin immunoassays in patients with renal impairment?
The extent of interference by digoxin-like immunoreactive substance in digoxin immunoassays in patients with renal impairment is lower than previously reported and varies by assay kit.
Answers are grounded in this paper and cite their sources.
DLIS interference may be less prevalent and kit-specific in renal impairment than previously thought; challenges earlier estimates while leaving clinical monitoring implications open.
A digoxin-like immunoreactive substance (DLIS) has been described in the sera of patients with renal impairment. To further investigate this problem, we measured digoxin in 50 patients with elevated serum creatinine using 4 commercial digoxin immunoassay kits (3 radioimmunoassay methods and 1 fluorescence polarization immunoassay technique). Ten of the patients were receiving digoxin therapeutically, while the remainder were not receiving the drug. Two of the radioimmunoassay kits detected low amounts of DLIS in 23% of the subjects not receiving digoxin, the highest level being 0.5 nmol/l. No DLIS was detected by the other radioimmunoassay kit or by the fluorescence polarization technique. The majority of renal patients receiving digoxin had similar results by all 4 methods, although 2 patients differed by 0.6 nmol/l as measured by 2 of the radioimmunoassay kits. We conclude that the extent of interference by DLIS in digoxin immunoassays in patients with renal impairment is not as great as has been previously reported.
No takes yet. Share an insight, caveat, or question.
Greenway et al. (2008) conducted an observational in Renal impairment (n=50). Digoxin immunoassay kits was evaluated on Detection of digoxin-like immunoreactive substance (DLIS). Digoxin-like immunoreactive substance was detected in only 23% of patients not receiving digoxin by two of four immunoassay kits, indicating less interference than previously reported.
Synapse has enriched 10 related papers. Consider them for comparative context: